Creating Value Through Breakthrough Science

We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors

More Info
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

December 8, 2022
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its

Read More
December 1, 2022
Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for

Read More
November 7, 2022
Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, has announced that its Phase II clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121). The randomized, double-blind, placebo- controlled study in patients with long covid who are suffering from debilitating fatigue has enrolled

Read More
November 3, 2022
Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million

Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive

Read More
October 13, 2022
Phase Four unveils game changing engine for LEO Constellations

Leveraging its new Block 2 architecture, Phase Four announces Max-V, a revolutionary plasma propulsion system available in 2023. Phase Four, the creator of the radio-frequency thruster for satellite propulsion, has announced that it will expand its Maxwell turn-key plasma propulsion line and offer satellite manufacturers an industry-first high performance engine

Read More
August 15, 2022
Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958

Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a

Read More
July 19, 2022
Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space

Weaving together digital engineering and technology, Parker Aerospace today announced collaboration with Lockheed Martin and DUST Identity. The alliance implements DUST technology to connect Parker Aerospace products with Lockheed Martin aircraft to track parts from build to delivery and maintenance. The collaboration optimizes Parker Aerospace product traceability and supply chain

Read More
June 29, 2022
Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735,

Read More
June 14, 2022
Cambridge Epigenetix names Peter Fromen as Chief Executive Officer

Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board. Professor

Read More
June 8, 2022
Phase Four and Impulse Space to collaborate on multi-mode propulsion

Phase Four the creator of the radio-frequency thruster (RF Thruster) for satellite propulsion, has announced that it has signed a memorandum of understanding with Impulse Space, a Space 2.0 pioneer providing agile, economical last-mile space payload delivery capabilities. The companies seek to explore and collaborate on opportunities to develop and

Read More
March 29, 2022
Vascular Therapies completes $25 million private financing

Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, has announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company. Vascular Therapies plans to use the proceeds

Read More
March 22, 2022
Introducing Avari Wireless, a state-of-the-art designer & manufacturer of public safety DAS

Avari Wireless has announced the inception of their newly formed company, focusing largely on mission-critical public safety Distributed Antenna Systems (DAS). Built upon decades of DAS industry experience and with a competent team of seasoned sales, R&D and field service staff, Avari Wireless is well-positioned to meet the needs of

Read More
March 1, 2022
Paragraf raises $60 million in Series B financing

Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations.  The round included

Read More
February 2, 2022
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition

Read More
December 17, 2021
NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced the close of a USD 80 million Series C financing round. The financing round was co-led by Ysios Capital and Forbion Growth and joined by

Read More
November 16, 2021
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study

Read More
November 2, 2021
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing

Read More
October 28, 2021
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, has announced that it has raised €19 million in the first close of a Series B financing, which was co-led by new investor CR-CP Life Science Fund,

Read More
October 12, 2021
VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector

VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our

Read More
October 6, 2021
BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc.

BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

Greenwich

500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845

London

16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100